Dr Jerald Radich speaks about the treatment options that are available for chronic myeloid leukaemia (CML). Tyrosine kinase inhibitors such as imatinib dasatinib and erlotinib have allowed to clinicians to effectively treat CML without the need for transplantation. However there is still a portion of the patient population who cannot be effectively treated with these drugs. Dr Radich talks about some of the research that has been presented at ASH 2010, outlines how he believes CML treatment will progress in the next ten years and speaks about the role of patient advocacy groups. Dr Radich concludes by discussing the International CML foundation and the work this organisation does to combat CML in emerging countries.